RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Peking University Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05917431, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. clinical or pathological diagnosis of HCC

    Inclusion criterion 3

  3. Child-Pugh A or B (7 scores) liver function

    Inclusion criterion 7

  4. Eastern Cooperative Oncology Group performance status of 0-1

    Inclusion criterion 2

  5. with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05917431, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • age ≥ 18 years
  • Eastern Cooperative Oncology Group performance status of 0-1
  • clinical or pathological diagnosis of HCC
  • with unresectable locally advanced or oligometastatic HCC (metastatic lesions ≤ 5, metastatic organs ≤ 3, may involve extrahepatic lymph nodes or distant organs apart from brain)
  • at least one measurable lesion according to mRECIST criteria
  • all lesions could be included in radiation target volume
  • Child-Pugh A or B (7 scores) liver function
  • patients are allowed to receive systemic therapy previously other than tislelizumab plus regorafenib
  • adequate hematological and renal function
  • life expectancy ≥ 3 months;
  • willing to participate in the study and give written informed consent

Exclusion Criteria:

  • a history of liver transplantation
  • with severe cirrhosis complications, including a history of esophagogastric variceal bleeding, hepatic encephalopathy, and massive ascites
  • with active autoimmune diseases or a history of autoimmune disease
  • with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
  • allergic to the ingredient of tislelizumab or regorafenib
  • with recurrent lesions treated with radiotherapy previously
  • prescribed radiation does could not be delivered due to dose limits to organs at risk (OAR)
  • intolerable to radiation or systemic treatment because of cardiac insufficiency, uncontrolled high blood pressure
  • a history of other malignancies, except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

Quoted from ClinicalTrials.gov, NCT05917431, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05917431, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05917431